# Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

> **NCT05364762** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Itacitinib
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT05364762
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-23
- **Primary completion:** 2026-05-22
- **Final completion:** 2026-05-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364762, "Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05364762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*